Gastroenterology 2006, 131: 1734–1742.PubMedCrossRef 30. Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P: A phase I study Selleckchem Veliparib of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2009, 15:

5910–5916.PubMedCrossRef 31. Casali PG, Joensuu H, Martin Broto J: Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST). J Clin Oncol (abstract) 2010, 28: 7s.CrossRef 32. Liegl B, Kepten I, Le C: Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008, 216: 64–74.PubMedCrossRef 33. Conley AP, Araujo D, Ludwig J: A randomized phase II study of perifosine (P) plus

imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol (abstract) 2009, 27: 15s.CrossRef 34. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Ro 61-8048 Eisenberg B, von Mehren M, Godwin AK: Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 2008, 105: 8387–8392.PubMedCrossRef 35. Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, Maki RG, DeMatteo RP, Besmer P, Antonescu CR: Molecular characterization of pediatric gastrointestinal stromal

tumors. Clin Cancer Res 2008, 14: 3204–3215.PubMedCrossRef 36. Pantaleo MA, Astolfi A, Di Battista M, Heinrich MC, Paterini P, CX-5461 purchase Scotlandi K, Santini D, Catena F, Manara MC, Nannini M, Maleddu A, Saponara PRKD3 M, Lolli C, Formica S, Biasco G: Insulin-like growth factor 1 receptor (IGF1r) expression in wild-type GIST: a potential novel therapeutic target. Int J Cancer 2009, 125: 2991–2994.PubMedCrossRef 37. Janeway KA, Zhu MJ, Barretina J, Perez-Atayde A, Demetri GD, Fletcher JA: Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int J Cancer 2010, 127 (11) : 2718–22.PubMedCrossRef 38. Braconi C, Bracci R, Bearzi I, Bianchi F, Sabato S, Mandolesi A, Belvederesi L, Cascinu S, Valeri N, Cellerino R: Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 2008, 19: 1293–1298.PubMedCrossRef 39. Nakai N, Ishikawa T, Nishitani A, Liu NN, Shincho M, Hao H, Isozaki K, Kanda T, Nishida T, Fujimoto J, Hirota S: A mouse model of a human multiple GIST family with KIT-Asp820Tyr mutation generated by a knock-in strategy. J Pathol 2008, 214: 302–311.PubMedCrossRef 40. Rubin BP, Antonescu CR, Scott-Browne JP, Comstock ML, Gu Y, Tanas MR, Ware CB, Woodell J: A knock-in mouse model of gastrointestinal stromal tumors harboring kit K641E. Cancer Res 2005, 65: 6631–6639.PubMedCrossRef 41.